

## **RECORDATI TO PRESENT THE FIRST QUARTER 2021 RESULTS AND THE 2021-2023 STRATEGY AND OUTLOOK UPDATE**

Milan, 28 April 2021 – Recordati management will be hosting a conference call with the financial community on:

**Thursday, 6 May at 3:00 pm CET (2:00 pm GMT)**

Recordati's first quarter 2021 results and 2021-2023 strategy and outlook update will be presented.

Dial-in numbers are:

Italy	+39 02 8058811, toll free 800 213 858
UK	+44 1 212818003, toll free 800 0156384
USA	+1 718 7058794, toll free 855 2656959
France	+33 170918703
Germany	+49 69 17415713

Callers are invited to dial-in 10 minutes before conference time. If conference operator assistance is required during the connection, please digit \* followed by 0.

A set of slides, which will be referred to during the meeting, will be available on our website [www.recordati.com](http://www.recordati.com) under Investors/Company Presentations.

A recording of the proceedings will be subsequently placed on the website [www.recordati.com](http://www.recordati.com).

***Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

Recordati website: [www.recordati.com](http://www.recordati.com)

### Investor Relations

Federica De Medici  
(39) 02 48787146  
e-mail: [investorelations@recordati.it](mailto:investorelations@recordati.it)

### Media Relations

Studio Noris Morano  
(39) 02 76004736, (39) 02 76004745  
e-mail: [norismorano@studionorismorano.com](mailto:norismorano@studionorismorano.com)

**RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.**

Sede Legale  
VIA M. CIVITALI, 1  
20148 MILANO, ITALIA  
TEL. (39) 0248787.1  
FAX (39) 0240073747

CAPITALE SOCIALE € 26.140.644,50 i.v.  
REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150  
CODICE FISCALE/P. IVA 00748210150  
R.E.A. MILANO 401832

Società Soggetta all'attività di Direzione e Coordinamento di Rossini Luxembourg S.à.r.l